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Lysyl-tRNA Synthetase Mutations
in a Patient with Peripheral Neuropathy
Heather M. McLaughlin,1 Reiko Sakaguchi,2 Cuiping Liu,2 Takao Igarashi,2 Davut Pehlivan,3
Kristine Chu,4 Ram Iyer,5 Pedro Cruz,4 Praveen F. Cherukuri,4 Nancy F. Hansen,4
James C. Mullikin,4,6 NISC Comparative Sequencing Program,6 Leslie G. Biesecker,7
Thomas E. Wilson,1,5 Victor Ionasescu,8 Garth Nicholson,9,10 Charles Searby,8 Kevin Talbot,11
Jeffrey M. Vance,12 Stephan Zu¨chner,12 Kinga Szigeti,3,13 James R. Lupski,3,14,15 Ya-Ming Hou,2
Eric D. Green,4,6 and Anthony Antonellis1,16,*
Charcot-Marie-Tooth (CMT) disease comprises a genetically and clinically heterogeneous group of peripheral nerve disorders character-
ized by impaired distal motor and sensory function. Mutations in three genes encoding aminoacyl-tRNA synthetases (ARSs) have been
implicated in CMT disease primarily associated with an axonal pathology. ARSs are ubiquitously expressed, essential enzymes respon-
sible for charging tRNA molecules with their cognate amino acids. To further explore the role of ARSs in CMT disease, we performed
a large-scale mutation screen of the 37 human ARS genes in a cohort of 355 patients with a phenotype consistent with CMT. Here
we describe three variants (p.Leu133His, p.Tyr173SerfsX7, and p.Ile302Met) in the lysyl-tRNA synthetase (KARS) gene in two patients
from this cohort. Functional analyses revealed that two of these mutations (p.Leu133His and p.Tyr173SerfsX7) severely affect enzyme
activity. Interestingly, both functional variants were found in a single patient with CMT disease and additional neurological and non-
neurological sequelae. Based on these data, KARS becomes the fourth ARS gene associated with CMT disease, indicating that this family
of enzymes is specifically critical for axon function.Charcot-Marie-Tooth (CMT) disease represents a geneti-
cally and clinically heterogeneous group of peripheral
neuropathies, with a prevalence of 1 in 2500 individuals.1
The major clinical features of CMT include distal muscular
weakness and wasting, impaired sensation, steppage gait,
pes cavus, and diminished deep-tendon reflexes.2,3
Broadly, CMTcan be subdivided into two classes according
to electrophysiological criteria.2 In CMT1, patients exhibit
decreasedmotor nerve conduction velocities (MNCVs) and
demyelination of peripheral nerve axons. In CMT2,
patients do not show primary demyelination but do
exhibit axonal loss accompanied by decreased amplitudes
of evoked nerve responses.
Aminoacyl-tRNA synthetases (ARSs) are a ubiquitously
expressed, essential family of enzymes responsible for
charging tRNA molecules with their cognate amino acids
in the cytoplasm and mitochondria.4 Interestingly, muta-
tions in three genes encoding aminoacyl-tRNA synthetases
have been implicated in CMT disease characterized by an
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tRNA synthetase.5–7 Although the molecular pathology
of axonopathy associated with ARS mutations remains
unclear, several mutant forms of GARS and YARS impair
tRNA charging, cell viability in yeast assays, and cellular
localization in mammalian cells, suggesting that impaired
enzyme function may play a role in disease onset, with
neurons harboring very long axons more susceptible to
tRNA charging deficits.7,8 Combined, these findings
strongly suggest that all genes encoding an ARS are excel-
lent candidates for CMT disease. We therefore carried out
a sequencing-based mutation screen of the 37 ARS genes
in a cohort of 355 patients with a phenotype consistent
with CMT and no known disease-causing mutation. The
appropriate, institute-specific review boards approved all
studies performed herein, and informed consent was
obtained from all subjects. This study revealed four
protein-coding variants (including one previously
described polymorphism) in the lysyl-tRNA synthetase
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Figure 1. Characterization, Conserva-
tion, and Localization of KARS Variants
(A) Representative sections of sequence
chromatograms are shown for the regions
encompassing each identified KARS
variant in the indicated individuals.
Arrows denote the variant (present in the
heterozygous state), with the predicted
amino acid changes depicted above.
(B) Chromatograms from allele-specific
sequencing of an ~3.7 kb PCR-generated
genomic segment spanning the two KARS
variants (p.Leu133His and p.Tyr173-
SerfsX7) identified in patient BAB564.
Arrows indicate each mutation. Note that
each variant was identified on separate
alleles, indicating that this patient is
a compound heterozygote.
(C) For each of the four detected variants,
the affected amino acid is shown along
with the flanking KARS protein sequence
in multiple, evolutionarily diverse species.
Note that each specific amino acid change
is given at the top, with the relevant posi-
tion depicted in red for each protein
sequence. Dashes indicate gaps in the
sequence alignment.
(D) The known functional domains of the
KARS protein are indicated in yellow
(tRNALys-binding domain) and blue (core
catalytic domain).16q23.1 and encodes the enzyme responsible for charging
tRNALys molecules. Importantly, KARS is the only locus in
the human genome encoding an enzyme responsible for
tRNALys charging and is required in both the cytoplasm
and mitochondria for protein translation.9
OneKARSvariantwas identified in theheterozygous state
in patient BAB663 (Figure 1A; BAB663): c.906C>G, which
predicts p.Ile302Met. This patient’s pedigree indicates an
apparent autosomal-dominant mode of inheritance
(see Figure S1 available online). Electrophysiological studies
revealed that BAB663 exhibited normal MNCVs in all
nerves tested, accompanied by normal amplitudes of
evoked nerve response (6 mV, 7 mV, 8 mV, 11 mV, 7 mV,
and 4 mV in the left median, left ulnar, right median, right
ulnar, left peroneal, and left post-tibialnerves, respectively).
Distal motor latencies were prolonged (7.2 ms in the right
and left median nerves, 3.6 ms in the left ulnar nerve,
4.2 ms in the left ulnar nerve, 7.6 ms in the left peronealThe American Journal of Human Generve, and 5.8 ms in the left tibial
nerve). Thus, this patient has a pheno-
type consistent with hereditary
neuropathy, with liability to pressure
palsies (HNPP [MIM 162500]).10
Two additional KARS variants were
identified in a patient with interme-
diate CMT, developmental delay,
self-abusive behavior, dysmorphic
features, and vestibular Schwannoma
(Figure 1A; BAB564): c.398T>A,which predicts p.Leu133His, and c.524_525insTT, which
predicts a frameshift mutation p.Tyr173SerfsX7. BAB564
exhibited MNCVs of 39.5 m/s and 30.6 m/s in the median
and ulnar nerves, consistent with an intermediate CMT
phenotype.11 In addition, this patient displayed decreased
amplitudes of evoked motor response in these nerves
(0.5 mV). More detailed molecular analysis of BAB564
(involving PCR amplification, cloning, and sequencing
the ~3.7 kb segment encompassing the two detected vari-
ants) revealed that this individual is a compound heterozy-
gote for p.Leu133His and p.Tyr173SerfsX7 (Figure 1B).
Because this individual was adopted, these efforts were crit-
ical for distinguishing between a complex allele and
compound heterozygosity (DNA samples from the biolog-
ical parents are unavailable). Finally, p.Thr623Ser was iden-
tified in 31 out of 710 chromosomes studied (frequency ¼
0.044). This variant is present in dbSNP (rs6834), indi-
cating that p.Thr623Ser represents a rare polymorphism.netics 87, 560–566, October 8, 2010 561
Table 1. ARS Missense Variants Identified in Patients BAB564 and BAB663
BAB564 BAB663
Gene MIM Variant Notes Gene MIM Variant Notes
EPRS 138295 p.Asp308Glu rs22303011 EPRS 138295 p.Asp308Glu rs22303011
FARS2 611592 p.Asn280Ser rs112430111 FARSB 609690 p.Val585Ile rs71851
FARSB 609690 p.Val585Ile rs71851 IARS 600709 p.Lys1182Glu rs5561551
KARS 601421 p.Leu133His This study KARS 601421 p.Ile302Met This study
RARS 107820 p.Val3Ile rs2449031 NARS 108410 p.Asn218Ser 2/7102
RARS 107820 p.Phe397Tyr rs23057341 RARS 107820 p.Val3Ile rs2449031
TARS 187790 p.Ala95Glu 1/7102,3 YARS2 610957 p.Glu191Val 10/7102
1 dbSNP accession number.
2 Number of chromosomes identified in total patient cohort.
3 Does not affect TARS enzyme function in aminoacylation assays (Jiqiang Ling and Dieter So¨ll, personal communication).Samples from patients BAB663 and BAB564 were
screened for mutations in other genes previously impli-
cated in CMT disease, including the CMT1A duplication
and point mutations in AARS, EGR2 (MIM 129010),
GARS, GDAP1 (MIM 606598), GJB1 (MIM 304040), MPZ
(MIM 159440), NEFL (MIM 162280), PMP22 (MIM
601097), PRX (MIM 605725), SIMPLE (MIM 603795),
SOX10 (MIM 602229), LMNA (MIM 150330), TDP1 (MIM
607198), MTMR2 (MIM 603557), and YARS. Patient
BAB663 is heterozygous for p.Arg238His GJB1,12
p.Thr87Thr SIMPLE,13 and the 1.4 Mb PMP22 deletion.14
Interestingly, the PMP22 deletion and p.Arg238His GJB1
variant have previously been reported as pathogenic in
HNPP and CMTX1 (MIM 302800), respectively.14,15 No
mutations or copy number variations were detected in
patient BAB564. Importantly, this includes MPZ and
YARS, both of which have been associated with interme-
diate CMT.16 To further exclude known causes of interme-
diate CMT, we screened BAB564 for DNM2 (MIM 602378)
mutations; these studies were also negative. Thus, BAB564
does not carry mutations in genes previously implicated in
intermediate CMT.11,16 Finally, six variants in other ARS
genes were identified in each individual, although none
are likely to be pathogenic (Table 1).
To determine whether the KARS variants are benign, we
performed appropriate genotyping assays on DNA samples
from neurologically normal controls of European decent
(NINDS/Coriell). The p.Leu133His, p.Ile302Met, and
p.Tyr173SerfsX7 variants were not detected in 1036, 1094,
and 1098 chromosomes tested, respectively. We also
screened all KARS protein-coding sequences for mutations
in 95 individuals from the ClinSeq cohort.17 The only
protein-coding variant identified was p.Thr623Ser, which
occurred in 11 out of 190 chromosomes (frequency ¼
0.058).
The evolutionary conservation of each affected KARS
residue was assessed by aligning protein sequences from
KARS orthologs from multiple species (Figure 1C). Leucine
133 was conserved among all species analyzed, with the
exception of plant, yeast, and bacteria. Isoleucine 302562 The American Journal of Human Genetics 87, 560–566, Octoberwas conserved among all species examined, including
yeast and bacteria. Tyrosine 173 was conserved among all
species analyzed, with the exception of mosquito and
bacteria. In contrast, threonine 623 was not conserved
between human and rodents and resides in a region that
does not align with protein sequences from nonvertebrate
species. Thus, the three rare KARS variants identified in our
patient cohort reside at remarkably well-conserved amino
acids, suggesting that they have a potential functional
impact on the KARS protein.
We further computationally predicted the effect of each
variant on protein function with the MuPro, PolyPhen,
PolyPhen2, SIFT, Align GVGD, and CDPred algorithms
(Table 2).18–23 It is notable that each of the known
disease-associated GARS, YARS, and AARSmutations is pre-
dicted to be pathogenic by at least three of these six algo-
rithms (Table 2). The p.Leu133His and p.Ile302Met KARS
variants are predicted to interfere with protein function
by four and three of the six algorithms, respectively. The
p.Tyr173SerfsX7 KARS variant could not be analyzed,
because these algorithms are unable to predict the effect
of frameshift mutations; however, this variant is predicted
to represent a null allele via nonsense-mediated decay.
Importantly, the p.Thr623Ser polymorphism was pre-
dicted to be pathogenic by only one of the six algorithms.
The KARS holoenzyme exists in dimeric and tetrameric
forms.24 We mapped each affected KARS residue onto the
crystal structure of the human enzyme to examine the
amino acid position and structural relationship to func-
tional domains that could potentially alter enzyme func-
tion. Leucine 133 is located within an N-terminal
anticodon-binding domain (Figure 1D) and is adjacent to
the dimer-dimer interface (Figures 2A–2C). This interface
may be involved in interactions between KARS and various
binding partners, including p38 (MIM 600859) in the
mammalian multisynthetase complex, the HIV-1 Gap
protein, and mutant forms of SOD1 (MIM 147450) found
in patients with amyotrophic lateral sclerosis (MIM
105400).24–26 The p.Leu133Hismutation is likely to impact
some of these interactions. The p.Tyr173SerfsX7 variant8, 2010
Table 2. Computational Predictions of KARS Variant Pathogenicity
Gene Variant MUPro1 PolyPhen2 PolyPhen23 SIFT4 Align GVGD5 CDPred6
GARS p.Glu71Gly SVM ¼ 1.007 2.217 0.997 0.017 C657 77
GARS p.Leu129Pro SVM ¼ 1.007 2.217 1.007 0.007 C657 87
GARS p.Gly240Arg SVM ¼ 0.30 2.317 0.997 0.007 C657 87
GARS p.Gly526Arg SVM ¼ 0.00 2.797 1.007 0.007 C657 117
YARS p.Gly41Arg SVM ¼ 0.84 2.497 1.007 0.007 C657 127
YARS p.Glu196Lys SVM ¼ 1.007 0.63 0.997 0.17 C557 2
AARS p.Arg329His SVM ¼ 0.777 3.047 1.007 0.007 C25 107
KARS p.Leu133His SVM ¼ 0.617 0.11 0.997 0.06 C657 47
KARS p.Ile302Met SVM ¼ 0.867 0.63 0.36 0.11 C557 67
KARS p.Thr623Ser SVM ¼ 0.627 1.20 0.01 0.25 C0 þ1
1 Support Vector Machine (SVM) scores < 0 indicate a decrease in protein stability.
2 PolyPhen scoresR 1.5 indicate a prediction of pathogenic.
3 PolyPhen2 scores of ~1 indicate a prediction of pathogenic.
4 SIFT scores % 0.05 indicate a prediction of pathogenic.
5 Grantham variation (GV) and Grantham difference (GD) classes R C55 indicate a prediction of pathogenic.
6 CDPred delta scores % 3 indicate a prediction of pathogenic.
7 Denotes a pathogenic prediction.resides in the anticodon-binding domain (Figure 1D) and
predicts a complete loss of the catalytic domain. Isoleucine
302 resides in the catalytic domain (Figure 1D) and is also
adjacent to the dimer-dimer interface (Figures 2A–2C).
Thus, p.Ile302Met may also affect the association between
KARS and binding partners. Threonine 623 is unresolved
in the crystal structure. Importantly, these analyses reveal
similarities between p.Leu133His and p.Ile302Met KARS
and disease-associated GARS mutations; most GARS muta-
tions affect residues that reside on the dimer interface of
the holoenzyme.27
KARS catalyzes the aminoacylation of tRNALys in the
cytoplasm and mitochondria via a two-step aminoacyla-
tion reaction.28 Importantly, 7 out of 10 disease-associated
GARS and YARSmutations tested to date impair aminoacy-
lation activity.4 We investigated the ability of each KARS
variant to catalyze the aminoacylation reaction in vitro.
Human cytoplasmic tRNALys was synthesized by in vitro
transcription and was used as the substrate for aminoacyla-
tion. Analysis of the catalytic efficiency (kcat/Km) of amino-
acylation showed that the p.Thr623Ser and p.Ile302Met
variants maintain normal catalytic activity, indicating
that these variants do not negatively affect aminoacyla-
tion. In contrast, p.Leu133His severely impairs enzyme
activity, resulting in an ~94% loss of catalytic efficiency
of aminoacylation relative to wild-type KARS (Table 3;
Figure 2D).
Many GARS and YARS mutations do not complement
deletion of the corresponding yeast orthologs.7,8 To further
assess for defects in KARS enzyme function, we modeled
each KARS variant in the yeast ortholog (KRS1; Table 4)
and determined the effect on yeast cell viability via
complementation assays. A haploid yeast strain with the
endogenous KRS1 deleted (krs1D) was maintained viaThe Americtransformation with a wild-type copy of KRS1 on a URA3-
bearing vector (pRS316). Experimental alleles were gener-
ated on a LEU2-bearing vector (pRS315) and transformed
into the above strain, and their viability was assessed by
analysis of growth on 5-fluoroorotic acid (5-FOA). Wild-
type KRS1 vector supported significant growth, whereas
an insert-free pRS315 construct did not (Figure 2E), consis-
tent with our experimental vector harboring functional
KRS1 and with KRS1 being an essential gene, respectively.
The p.Asn103His and p.Ile277Met KRS1 variants allowed
growth in a manner consistent with wild-type KRS1. In
contrast, p.His146PhefsX12 KRS1 could not complement
the krs1D allele (Figure 2E), consistent with p.Tyr173-
SerfsX7 KARS representing a null allele.
In summary, we report three rare KARS variants in two
patients with peripheral neuropathy. The p.Ile302Met
variant was discovered in the heterozygous state in an indi-
vidual with clinical electrophysiological evidence for
HNPP and was molecularly found to harbor the common
1.4 Mb deletion, including PMP22. Although p.Ile302Met
resides at a residue within the catalytic core of the enzyme
that is conserved between human and bacteria, we were
unable to show an effect on enzyme function via aminoa-
cylation and yeast growth assays. Thus, the PMP22
deletion should be considered the primary pathogenic
mutation in BAB663. However, it will be important
to determine whether or not the PMP22 deletion,
p.Arg238His GJB1, and p.Ile302Met KARS interact to
modify the phenotype in this patient; several recent
studies suggest the potential for a more severe neuropathy
phenotype associated with variants at more than one
CMT locus.29–31
The p.Leu133His and p.Tyr173SerfsX7 variants were
identified in the compound heterozygous state in a patientan Journal of Human Genetics 87, 560–566, October 8, 2010 563
Figure 2. Functional Consequences of KARS Variants
(A–C) An illustration of the KARS protein crystal structure is shown for the monomer (A), dimer (B), and tetramer (C). The anti-codon
binding and catalytic domains are indicated in (A). The position of residues L133 and I302 are indicated in red and black, respectively.
Note that L133 resides at the tetramer interface in (C).
(D) Initial aminoacylation rates, V0 (pmol/s), of wild-type KARS (blue squares) and p.Leu133His KARS (red circles) were plotted against
tRNA concentration and fit to the Michaelis-Menten equation. Error bars indicate standard deviation.
(E) Representative cultures of the indicated yeast strains were inoculated and grown on solid growth medium containing 5-FOA. Each
strain was previously transfected with a vector containing no insert (pRS315), wild-type KRS1 (WT KRS1), or the indicated mutant form
of KRS1 that modeled a human KARSmutation (see Table 4). Before inoculating on 5-FOA-containing medium, each strain was diluted
1:10 or 1:50 in water.with intermediate CMT, developmental delay, self-abusive
behavior, dysmorphic features, and vestibular Schwan-
noma. The p.Tyr173SerfsX7 variant represents a loss-of-
function allele, and p.Leu133His represents a severely
hypomorphic allele in yeast growth and aminoacylation
assays, respectively. Combined, these data indicate that
the patient has a severe depletion of charged tRNALys in
both the cytoplasm and mitochondria. It is important to
consider these loss-of-function mutations in the context
of the CMT and non-CMT phenotypes observed in thisTable 3. Enzyme Kinetics of Variant KARS Proteins in
Aminoacylation Assays
KARS
Enzyme Km (mM) kcat (s
1)
kcat/Km
(s1mM1)
Relative
Activity
Wild-type 1.8 5 0.9 1.4 5 0.1 0.8 1
p.Leu133His 5.8 5 2.4 0.3 5 0.3 0.05 0.06
p.Ile302Met 2.1 5 0.8 2.7 5 1.6 1.3 1.6
p.Thr623Ser 3.5 5 0.1 4.0 5 0.7 1.1 1.4
564 The American Journal of Human Genetics 87, 560–566, Octoberpatient. To date, three ARS genes have been implicated in
CMT.5–7 The encoded enzymes either are bifunctional
(GARS charges tRNA in both the cytoplasm andmitochon-
dria) or charge tRNA in the cytoplasm (YARS and AARS). In
each case, the phenotypes are dominant and the muta-
tions are missense or in-frame deletions. Furthermore,
each mutation has been associated with a loss of function,
as observed by impaired tRNA charging, inability toTable 4. Human KARS Variants Modeled in the Yeast Ortholog
KRS1
Human KARS1 Yeast KRS12
p.Leu133His p.Asn103His
p.Tyr173SerfsX7 p.His146PhefsX12
p.Ile302Met p.Ile277Met
1 Amino acid coordinates correspond to GenBank accession number
NP_001123561.1.
2 Amino acid coordinates correspond to GenBank accession number
NP_010322.1.
8, 2010
complement the deletion of the yeast ortholog, and/or
reduced localization of the ARS enzyme to axons.5,7,8,27
Because haploinsufficiency for Gars does not cause
a CMT-like phenotype in mouse,32 a dominant-negative
effect has been proposed.4 Such an effect would reduce
tRNA charging levels to ~25%, a level that may breach
a threshold required by neurons with particularly long
axons.6 Our functional analyses suggest that KARS
charging activity is reduced to well below 25% (~6%) in
patient BAB564. As such, compound heterozygosity for
a null and severely hypomorphic KARS allele may be ex-
pected to cause a more severe or complex phenotype
than heterozygosity for a dominant-negative ARS muta-
tion. It is also possible that additional genetic complexities
could be associated with the non-CMT sequelae—in partic-
ular, the vestibular Schwannoma often associatedwithNF2
mutations (MIM 607379).33 Therefore, detailed analysis in
a vertebrate model system will be required to tease out the
contribution of each KARS allele to the neuronal and non-
neuronal phenotypes observed in patient BAB564.
The studies presented here describe the fourth associa-
tion between ARS gene mutations and CMT and outline
the importance of using informative and relevant func-
tional assays as a follow-up to large-scale mutation screens.
Indeed, our efforts illustrate some of the issues common to
contemporary human genetics and genomics; for example,
although we have the capacity to sequence large cohorts of
patients, the analysis of small families and sporadic cases is
often key for assessing the role of specific genes in human
disease. In these and other ‘‘gene discovery’’ cases, relevant
and informative functional assays provide critical evidence
for the pathogenicity of uncharacterized variants.
KARS protein orthologs from multiple species were
derived from the following GenBank accession numbers:
human (Homo sapiens, NP_00112356), chimpanzee (Pan
troglodytes, XP_511115.2), orangutan (Pongo abelii, NP_
001123561), dog (Canis familiaris, XP_536777.2), mouse
(Mus musculus, NP_444322), rat (Rattus norvegicus, NP_
001006968), chicken (Gallus gallus, NP_001025754), frog
(Xenopus laevis, NP_001080633), zebrafish (Danio rerio,
NP_001002386), fruitfly (Drosophila melanogaster, NP_
572573), mosquito (Anopheles gambiae, XP_310792), algae
(Chlamydomonas reinhardtii, XP_001697493), worm (Cae-
norhabditis elegans, NP_495454), plant (Arabidopsis thali-
ana, NP_187777), yeast (Saccharomyces cerevisiae, NP_
010322), bacteria (Escherichia sp. 1_1_43, ZP_04871218).Supplemental Data
Supplemental Data include one figure and can be found with this
article online at http://www.cell.com/AJHG/.Acknowledgments
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